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INFORMATION  POLICY  SHEET 
EXTENSION  OF  PHARMACEUTICAL  DIRECTIVES  TO 
MEDICINAL  PRODUCTS  NOT  YET  COVERED 
1. PEOPLE  OR  GROUPS  AFFECTED. 
The  primary objective of  this package  of proposals  is to extend  the  scope 
of  the  Community  pharmaceutical  directives to  cover  immunological  medicinal 
products,  medicinal  products  derived  from  human  blood,radiopharmaceuticals 
and  non-proprietary  (generic)  medicinal  products  and  as  such  it will  be  of 
particular  interest to  the manufacturers  of  the  products  concerned  • 
In  addition,  the  package  contains  a  series of general  amendments  to the 
pharmaceutical  directives  relating to  information  for  patients about  medicines, 
manufacturing  standards  and  exports  to the  third world,  which  will  be  of 
interest  to all  pharmaceutical  manufacturers,  to other  health  professionals 
. anq  to  consum.ers. 
2.  PREPARING  THE  PROPOSALS. 
a)  !QQQ~2ti~~-2~~~~!~ 
This  package of  proposals  would  bring  immunological  medicinal  products 
<sera,  vaccines,  toxins,  allergens  etc.)  blood  products and  radio-
pharmaceuticals  within  the  scope  of  the  Community  Directives on  medicinal 
products  for  the  first  time. 
b>  fQ~~~l!~!iQ~_el_!~~-fQ~~i~~iQ~~~-~~~~i£~~ 
This  package of proposals  results  not  only  from  a  commitment  in  the 
White  Paper  on  the  Internal  Market  but  also  from  a  mandate  unanimously 
conferred to the  Commission  by  the  Council  in  Article 5  of  Directive 
87/22/EEC.  All  the  Member  States  support  the objectives of  the  package 
the details of which  have  been  drafted  in  close consultation with  national 
and  industry experts  and  representatives  of other  interested groups. 
These  consultations will  continue during  the  elaboration of  the  very 
detailed  implementing  directives on  the testing of  each  of  the  categories 
of  medicines  concerned. 
3.  PARTICULAR  INFORMATION  ACTIVITIES. 
Press  release  for  specialist  journals  in  medical/pharmaceutical  field. 
Summary  mention  in more  general  press  releases  dealing  with  the  implementation 
of  the  internal  market. 
2· TIMETABLE  ANNEX 
Given  the  importance of  attaining  the  White  Paper  target  date of  1992  for  the 
realisation of  the  internal  market  and  the  public  health  importance  of  the 
categories of  product  covered  by  these proposals,  it  is desirable that  these 
proposals  should  come  into effect  by  1  January  1991  at  the  Latest.  To  this  end, 
the  following  timetable  is proposed  : 
.  ~-
Opinion of  the  Economic  and  Social  Committee  30  April  1988 
Opinion  of  the  European  Parliament  30  September  1988 
Adoption  of  a  common  position by  Council 
Conclusion of cooperation procedure  with  European 
and  adoption of directives  by  the  Council 
Entry  into  force  of the directives 
Parliament 
30 
31 
1 
April  1989 
December  1989 
January  1991 
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EXTENSION  OF  PHARMACEUTICAL  DIRECTIVES' 
TO  MEDICINAL  PRODUCTS  NOT  YET  COVERED 
EXPLANATORY,  MEMORANDUM 
\,:  1.'.,. 
When  it  adopted  Directive  75/319/EEC1  on  the  apprdximat~on ·of  provisions~ 
laid  down  by  law,  regulation  ~r  ~dministrativi  a~tion  relating  to 
proprietary medicinal  products,  the  Council  considered that the provisions 
of.that Directive and  those of the earlier Directive 65/65/EEC2,  "although 
appropriate,  are  inadequate for vaccines,  toxins  and  serums,  propr.ie·tary 
medicinal  products  based  on  ~uman blood  or blood  consiituent~,  propriet~ry 
medicinal  products  based  on  radio-active .  isoto.pes  and  homeopathic. 
proprietary  medicinal  products".  Article 34  of·  Dfrective  ,75/319/EEC 
therefore  excludes  these  products  from  the  scope  of  the  Community 
Directives. 
t.  •,  •  :.  t...  1 .  ~ 
The  inclusion  of  these  categorie~  of  products  within  Community  rules 
relating  to  medicinal  products  was  identified  by  the  ·Commission  as  a;· 
priority  in  the  legislative  programme· annexed  to  the  .White  Paper  on  ,the. 
Completion  of  the  Internal  Market.  This  work  was  given  further··impetus 
following  the adoption of  Council  D{rective 87/2i/EEC,of·22  December  198~
3 ,. 
Article 5 of  which  requires  the  Commission  to present  proposals within  one  .  . . 
year to harmonise,  along  the  lines of  Directiv~.75/319/EEC, the  conditions 
for  authorizing  the  manufacture  and  placing  on  the  m_arket'  of  the· 
proprietary  medicinal..  products  excluded  ·by  Article. 34,  ·-~·and ..  ,of, the. 
veterinary  medicinal  products  referred  to  in  Article  2<2>  of  Directive 
81/851/EEC4,  in  view  of  in  particular,  the ·safety·. problems . a,ri.sing  '_in 
production and  use. 
. \  ·..  ~  .  .  ; ' . 
.f)  • :  :  ~  ._.,.  : ...  ~  •. 
This  package··  .of· P.ropo~als'  is. presen:ted.  ·a~~·:·a  ·J}r.s,t_:  s~~Ji  t~wa~C:t~.' 'the.'· 
impl'ementatio.n  of  that  mandate.  . It  covers  medicinal ... products, b.as.ed.  on 
radio-active isotopes  <radiopharmaceuticals);  vaccines,  toxins,  serums  and 
allergens  (immunological  products);  and  medicinal  products  derived  from 
human  blood.  In addition,  the  Commission  is proposing  several detailed but 
important . changes  . to  the  general  Community  rules  relating  to  medicinal 
1  OJ  N°  L 147 of 9.6.1975,  p.  13 
2  OJ  N°  22  of 9.2.1965,  p.  369/65 
3  OJ  N°  L 15  of  17.1.1987, p.  38 
4  OJ  N°  L 317  of 6.11.1981,  p.  1 
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products.  These  changes  are  intended  in  particular  to  follow  up  the 
Resolution  of  the  European  Parliament  of  13  June  1986  on  the  Export  of 
Pharmaceutical  Products  to  the  Third  World  (Banotti  Resolution)  and  the 
Council  Conclusions of 15  May  1987  on  improvement  in the use  of proprietary 
medicinal  products  by  consumers5• 
These  proposals  have  been  drafted  in  extremely  close  collaboration  with 
national  experts,  using  the  Committee  for  Proprietary  Medicinal  Products, 
and  in  particular its working  party  on  the  quality  of  medicines,  and  the 
ad  hoc  biotechnology/pharmacy working  party.  There  have  also been  detailed 
consultations  with  the  pharmaceutical  industry,  and  with  groups 
representative  of  the  manufacturers  of  the  particular  products  concerned; 
radiopharmaceuticals,  vaccines, 
products  derived  from  human  blood, 
allergens  etc.  For  the  proposal  on 
an  ad  hoc  meeting  of  national  experts 
was  convened.  In addition, the  ser.vices of the  Commission·met  with  various. 
interested groups  to discuss different aspects of the·package. 
The  Commission  is  aware  that  these  proposals  do  not  entirely  cover  the 
mandate  conferred  upon  it  by  the  Council.  Work  on  a  proposal  to  bring 
homeopathic  medicinal  products  within  the  scope  of  the  Community 
pharmaceutical directives  has  met  with  certain difficulties,  arising  from 
the  fact  that  in  certain· Member  States. the  principles  of  homeopathy  are 
officially  recognised,  while  in  others  they  are  merely  tolerated.  The 
Commission  therefore  intends  to  continue  consultations  with  interested 
parties, and  will  present  appropriate proposals on  these products as  a  part 
of  the  general  proposals  for  a  definitive  system  for  the free  movement  of 
medicinal  products  within the  Community,  which  are scheduled for 1989.  In 
addition,  because of the  complexity  of  the  legislative provisions  involved, 
and  the  limited  resources available within the  Commission,  it has  not  been 
possible  to  bring  forward  proposals  to  cover  veterinary  vaccines  and 
veterinary  radiopharmaceuti cals  at  the  present  time.  Nevertheless,  in 
cooperation  with  the  Committee  for  Veterinary  Medicinal  Products,  the 
Commission  has  begun  a  survey of  the  relevant' national provisions,  and  it 
intends  to  bring  forward  appropriate  proposals  in  1988,  as  part  of  a 
general  review  of  the  Directives  relating  to  veterinary  medicinal 
products6• 
5  OJ  N°  C 178  of 7.7.87, p.  2 
6  Directives 81/851/EEC  and  81/852/EEC  of  28  September  1981,  OJ  N°  L 317  of 
6.11.1981,  p.  1  and  p.  16  respectively 
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THE  GENERAL  PROPOSAL  TO  AMEND  DIRECTIVES  65/65/EEC,  75/318/EEC  and 
75/319/EEC 
This  proposal  has  four  major  objectives:  to  extend  the  scope  of  the 
Directives  to  cover  non-proprietary  medicinal  products;  to  improve  the 
information  avai table  to  consumers  abo.ut  medicinal  products;  to  lay  down 
certain  provisions  governing  the  export  of  medicinal  products;  and  to 
improve  the  guarantees  of  the  quality  of  all  medicinal  products 
manufactured  within  the  Community,  irrespective  of  their  intended 
destination.  In addition,  this proposal  contains a  series of  incidental 
amendments  to  the  basic  Directives  which  result  from  the  extension  of the 
Directives  to  cover  radiopharmaceuticals,  immunological  products  and 
products derived from  human  blood. 
2.1.  Non-proprietary medicinal  products 
At  the present  time,  the  Community  pharmaceutical 'Directives  only  apply  to 
proprietary medicinal  products,  that  is "ready-prepared medicinal  products 
placed on  the market  under  a  special  name  and  in  a  special  pack".  However, 
in  recent  years,  increasing interest has  been  given to so-called  'generic' 
pharmaceuticals,  which  are  copies  of established products  and  are marketed 
under  the  international non-proprietary name,  either with  or without  a  logo 
or  trade  name  representing  their  own  manufacturer.  In  many  cases,  for 
commercial  reasons,  these products are marketed  with  a  special  name  or  in a 
special  pack,  and  are thus  covered  by  the  Community  Directives.  However, 
in other cases,  doubts  may  arise.  In  order to  resolve  any  ambiguities  in 
the  present  situation,  the  Commission  is  proposing  that  the  scope  of  the 
directives  be  extended  to  cover  all  industrially  produced  ready-made 
medicinal  products  which  are  placed on  the  market  in a  pharmaceutical  form 
which  may  be  used  without  further  processing.  This  change  will  fill  any 
gap  which  may  exist  in  the  cur~ent  provisions  and  will  enable  the 
manufacturers  of  the  products  concerned  to  benefit  from  a  wider  Community 
market.  It  will  also  provide  substantial  guarantees  for  patients  that 
these  products  are  manufactured  in  accordance  with  the  same  strict 
requirements  as  other  categories of  medicinal  products.  As  a  consequence 
of  this  change,  and  in  order  to  avoid  confusion,  the  Commission  is 
proposing  that  henceforth  Community  pharmaceutical  legislation  should 
simply  refer  to  'medicinal  products"  rather  than  "proprietary  medicinal 
products•. 
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2.2.  Information for  patients 
Article 6  of  Directive  75/319/EEC  has  already  harmonised  the  basic 
information  which  should  be  contained  in  patient  information  leaflets. 
However,  it is up  to the  Member  States  to decide  whether  or  not  a  leaflet 
should  be  included  with  the  packaging  of  a  medicinal  product.  In  its 
conclusions  of  15  May  1987,  the  Council  unanimously  requested  the 
Commission  to begin  studying the  possibility of  making  more  systematic the 
use,  and  more  legible  and  intelligible  the  content  of patient  information 
leaflets  accompanying  medicinal  products,  in particular  •over  the  counter 
products',  the purpose being to encourage  the  secure  and  appropriate use  of 
medicinal  products  and  to  satisfy  the  consumer's  wish  to  be  properly 
informed.  In addition, the Commission  and  the  Member  States were  requested 
to  exchange  their  experience  and  consult  widely  with  interested  circles, 
and  the  Commission  was  requested  to  prepare  a  report  for  the  Council, 
accompanied,  if appropriate,  by  suitable proposals. 
At  the  present  time,  there  are  substantial  variations  in  the  practice of 
Member  States  in  making  information  available  to  patients  about  medicinal 
products.  In  certain Member  States, patients are  provided with  information 
leaflets as  a  matter of course,  while  in others  leaflets are provided only 
rarely.  However,  a  number  of  Member  States are  reviewing their policies on 
this matter.  For  its part,  the  Commission  intends  to  begin  a  series  of 
studies on  the  problems  of presenting  information for  patients with  a  view 
to presenting appropriate proposals to the  Council  in 1990. 
Many  of  the  problems  associated  with  the  introduction  of  patient 
information  leaflets  result  from  the  difficulties  inherent  in  presenting 
complex  medical  and  scientific  information  in  a  manner  which  is 
comprehensible  to patients and  is not  unduly  alarmist.  These  problems  are 
particularly difficult  to  resolve  in the  case of  the more  potent  medicines 
which  are only available on  medical  prescription.  However,  in the case of 
those  relatively  simple  medicinal  products  which  are  intended  to  be 
purchased directly by  the  consumer  without  a  medical  prescription and  which 
are  used  for  the  relief of  minor  self-limiting ailments, these difficulties 
are  less apparent.  Indeed,  in the  latter case, it would  appear  that  clear 
and  comprehensive  information is the  indispensable corollary of  responsible 
self-medication.  The  Commission  is therefore  proposing that the  inclusion 
of a  patient  information  leaflet,  established in accordance  with  Article 6 
of  Directive 75/319/EEC,  should  be  obligatory  in the packaging of medicinal 
.1  •• 
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products  which  may  be  obtained  without  a  medical  prescription  unless  all 
the  information  required  by  that  Article  can  be  included  on  the  packaging 
of  the product,  in which  case  the  leaflet would  be  redundant. 
2.3.  Exports  of  medicinal  products 
Following  the  Resolution of  the  European  Parliament  of  13  June  1986  on  the 
export  of  pharmaceutical  products  to  the  third  world,  the  Commission 
undertook  a  series  of  consultations  with  Member  States  in  order  to 
determine  how  best  to  respond  to  the  concerns  of  the  Parliament.  In 
addition, the Commission  has  necessarily  had  to take  into consideration the 
need  to  ensure  that  any  proposals  were  administratively  feasible  and 
limited as  to their territorial effect. 
In  accordance  with  current  Community  pharmaceutical  legislation,  all 
manufacturers  of  medicinal  products  must  be  in  possession  of  a 
manufacturing  authorization.  To  avoid  any  possible  ambiguity  on  this 
point,  the  Commission  is proposing  that  Article 16  of  Directive 75/319/EEC 
should  explicitly  state  that  this  manufacturing  authorization  is  required 
even  though  all the  products  manufactured  are  intended  for  export.  Thus, 
the existing provisions of  Community  legislation,  and  the new  requirements 
discussed  in section 2.4.  below  will  apply.  At  the  request  either of  the 
exporting  manufacturer  or  the  authorities  of  the  recipient  country,  the 
Member  State  concerned  will  issue  a  certificate  in  accordance  with  the 
arrangements  agreed  by  the  World  Health  Organisation that  the  manufacturer 
is authorised to manufacture  medicinal  products.  In addition,  the  Member 
States  will  annex  to  the  certificate  the  approved  summary  of  the 
characteristics of  the product.  In  accordance  with  Articles 4a  and  4b  of 
Directive  65/65/EEC  as  amended  by  Directive  83/570/EEC7,  these  summaries 
must  be  established  by  Member  States for  all medicinal  products  authorised 
for  use  on  their  territories  by  May  1990  at  the  latest,  well  before  the 
date  the  proposal  is  scheduled  to  come  into  effect.  This  summary  will 
enable the  competent  authorities  in the  recipient  country to verify  rapidly 
the  authorised  conditions  of  use  for  a  product  in  the  exporting  country. 
Conversely,  the absence  of  a  summary  will  immediately alert the authorities 
of  the  recipient  country  to  the  fact  that  the  medicine  is  not  authorised 
for  use  in the  exporting  Member  State,  and  they  will  be  able  to  draw  the 
appropriate  conclusions  in  the  light  of  the  explanations  given  by  the 
company  and  the prevailing conditions  in the  recipient  country. 
7  OJ  N°  L 332  of 28.11.1983,  p.  1 
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At  the  present  time,  the  filember  States  are  obliged  by  Article 33  of 
Directive  75/319/EEC  to  notify  the  Committee  for  Proprietary  Medicinal 
Products  of  any  decision  to  suspend  or  withdraw  a  medicinal  product.  In 
the  future,  the  Commission  is  proposing  that  these  notifications  should 
also  be  made  available  to  WHO  for  the  information  of  third  countries. 
However,  relatively  few  decisions  to  suspend  or  withdraw  marketing 
authorisations are made  by  the  competent  authorities.  In many  cases,  the 
firm  concerned  unilaterally  withdraws  the  product  from  the  market  in 
advance  of  possible  regulatory  action.  In  such  cases,  the  regulatory 
authorities  of  other  countries  may  not  be  aware  that  the  product  has  been 
withdrawn  from  the  market.  To  remedy  this  situation,  the  Commission  is 
proposing  that  any  firm  which  unilaterally  withdraws  a  product  from  the 
market  should  be  obliged  to  notify  the  competent  authority  of  the  Member  . 
State  concerned,  who  would  then  be  obliged  to  inform  the  CPMP,  and  in 
appropriate cases,  the  WHO. 
2.4.  Obligations on  manufacturers 
At  the  present  time,  authorization  to  manufacture  medicinal  products  is 
granted  by  the  competent  authorities  of  the  filember  State  in  which  a 
manufacturer  is  established,  who  are  responsible  for  ensuring  that  the 
manufacturer satisfies the  legal  requirements  laid down.  The  Commission  is 
proposing  to supplement  these  provisions  by  introducing  into the  Directives 
a  specific  requirement  for  manufacturers  to  comply  with  the  principles  of 
good  manufacturing  practice  for  medicinal  products.  The  detailed 
rcquiren.ents  of  good  manufacturing  practice  would  be  laid  down  in  a 
specific  Directive  to  be  adopted  by  the  so-called  regulatory  committee 
procedure,  with  the  agreement  of  a  qualified majority of the  Member  States. 
In fact,  work  on  the drafting  of this  Directive is  already at an  advanced 
stage,  and  it is envisaged that it would  be  completed  in time to enable  the 
specific  Directive  to  come  into  force  at  the  same  time  as  the  framework 
proposal. 
2.5.  Incidental  Provisions 
The  proposal  also  cont@~ns certair.  ~rovisicns of  an  incid~ntal nQture  which 
result  from  the extension  of  the  scope  of  the  Directives.  First,  it  is 
thought  necessary  tn  introduce a  definition of  the  word  "therapeutic" into 
Directive  65/65/EEC  . tp  make  it  clear  that  the  concepts  of  "therapeutic 
effects"  or  "therapeutic  results"  cover  not  only  the  use  of  a  medicinal 
product  for  the  prevention  or  treatment  of  disease  but  also  its  use  for 
other medicinal  purposes,  such  as diagnosis.  Secondly,  the  requirements 
.I  •• - 9  -
concerning  the  labelUng  of  medicinal  products,  leaflets  and  approved 
product  summaries  are  being  amended  to  provide  that  in  appropriate  cases 
information  should  be  given  on  the  safe disposal  of  the  product.  This  is 
particularly  important  in  the  case  of  radio-active  medicinal  products  and 
certain  biologically  active  products,  but  the  problem  may  also  arise  in 
other cases. 
3.  THE  THREE  PROPOSALS  TO  EXTEND  THE  DIRECTIVES  TO  RADIOPHARMACEUTICALS, 
IMMUNOLOGICAL  PRODUCTS  AND  MEDICINAL  PRODUCTS  DERIVED  FROM  HUMAN  BLOOD 
3.1o  The  General  Approach 
The  three  proposals  to  extend  the  pharmaceutical  Directives  to  cover 
radiopharmaceuticals,  immunological  products  and  medicinal  products  derived 
from  human  blood  are  based  upon  a  common  approach.  In  each  case,  the 
proposal  sets  out  a  series  of  definitions  of  the  products  concerned  and 
establishes the  principle  that  these  products  may  be  placed  on  the  market 
only after  an  authorization  has  been  granted  by  the  competent  authority of 
the  Member  State(s)  in  which  they  are  to  be  marketed.  In  c..ddition,  the 
proposals  lay  down  certain  fundamental  requirements  for  each  of  these 
categories of  products.  However,  it  is  envisaged  that  the  Council  will 
delegate  to  the  Commission  the  power  to  adopt  the  detailed  changes  which 
are  necessary  to  Council  Directive  75/318/EEC  relating  to  analytical, 
pharmaco-toxicological  and  clinical  standards  and  protocols  in  respect  of 
the  testing  of  medicinal  products  to  take  account  of  the  particular 
characteristics  of  these  products.  In  order  to  implement  these  changes, 
the  Commission  will act  in cooperation with  the  Committee  on  the  Adaptation 
to  Technical  Progress  of  the  Directives  on  the  Removal  of  Technical 
Barriers to Trade  in the  Proprietary Medicinal  Products  Sector,  created by 
Directive  87/19/EEC,  using  the  so-called  regulatory  Committee  procedure, 
which  requires  the  approval  of  a  qualified  majority  of  the  Member  States 
for  the  adoption of the measures  by  the  Commission  <Procedure  III variant a 
of  Council  Decision 87/373/EEC  of  13  July 19878  laying down  the  procedures 
for  the exercise of  implementing  powers  conferred on  the  Commission>.  Work 
on  the  preparation  of  the  detailed  changes  to  the  testing  requirements  is 
in  progress  and  it  is  envisaged  that  this  will  continue  during  1988,  in 
parallel  with  the discussions  on  these  proposals,  so  that  the  changes  can 
be  formally  adopted  immediately  after  the  Council  approves  the  Directives 
and  come  into effect at  the  same  time. 
8  OJ  N°  L 197 of  18.7.1987,  p.  33 
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3.2. Particular  requirements  for  immunological  products 
The  proposal  on  immunological  products  covers  a  variety  of  products  of 
biological origin,  including  immune  sera,  vaccines, toxins and  allergens. 
The  provisions of  Directives 65/65/EEC  and  75/319/EEC  will apply  in full  to 
these  products,  although  certain  changes  will  need  to  be  made  to  the 
detailed  testing  requirements  of  Directive  75/318/EEC  and  certain  changes 
are made  to the  provisions governing  the declaration of  the qualitative and 
quantitative  composition  of  these  products  to  take  account  of  their 
biological  origin.  There  is  however  one  area  where  the  regulation  of 
immunological  products  requires  a  somewhat  different  approach  from  that 
used  with  other  categories of medicinal  products. 
This  relates to  the  requirements  for the  manufacture  of  vaccines.  In  the 
case  of  all  immunological  products,  it  is  important  that  manufacturers 
should be  able to attain high  levels of  batch-to-batch  consistency  in their 
manufacturing operations,  and  the  proposal  contains specific  provisions to 
this  effect.  However,  in  the  case  of  vaccines,  this  is  particularly 
important,  since a  failure  to attain consistency  in the biological activity 
of  the  vaccine  may  reduce  or  remove  the  protection  it  offers  against 
disease.  For  this  reason,  several  Member  States  operate  batch  release 
systems.  Thus,  samples  from  each  manufacturing  batch  of  a  vaccine must  be 
submitted  for  testing  by  a  state  laboratory  and  the  particular  batch  may 
only  be  placed  on  the  market  once  the  laboratory  has  authorised  its 
release.  The  Commission  is  proposing  that  Member  States  should  be 
permitted  to  continue these  arrangements  for  live vaccines,  vaccines  used 
for  the  primary  imrnunizaticn  of  infants  or  vaccines  used  in  public  health 
immunization  programmes.  A list of  the vaccines  concerned  is  included  in 
an  annex  to  the  proposal.  The  proposal  also  provides  for  the  mutual 
recognition  by  other  Member  States  of  the  first  batch  release  control 
conducted  within  the  Community  thus  preventing  any  unnecessary  repetition 
of the tests within the  Community. 
3.3.  Particular  requirements  for  products derived from  human  blood 
Within  the  Member  St~tes of  the  Community,  human  blood  for  the  rn~nuf~cture 
of  blood  products i: coltected by  voluntary donation.  The  national  blood 
collection  servi~;:?s  are  generally  organised  on  a  non~profit-making basis, 
and  because  of  th~  sp~cial nature of  the  products  involved,  the  co;.,mercicl.. 
manufacture  and  marketing  of  blood  products  is  either  prohibited  or 
severely  restrictedo  Each  Member  State  has  tended  to  aim  for 
self-sufficiency  in the  supply of  blood  and  blood products.  The  Commission 
.I  •. .• 
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considers that  it would  be  desirable  to  replace  this objective  of  national 
self-sufficiency  with  the  objective  of  self-sufficiency  at  the  Community 
level  at  least  for  medicinal  products derived from  human  blood • 
The  proposal  applies  to  medicinal  products  based  on  blood  constituentS 
which  are  industrially  prepared  by  public  or  private  establishements,  in 
particular  to  albumin,  coagulating  factors  and  immunoglobulins  of  human 
origin.  It  does  not  cover  whole  blood,  plasma  or  blood  cells.  The 
proposal  establishes  the  principle  that  all  manufacturers  must  satisfy  the 
.... 
provisions  of  the  general  pharmaceutical  Directives,  in  particular  as 
regards  manufacturing  and  marketing  authorizations.  In  addition,  the 
proposal  recognises  the  substanti~l  amount  of  work  which  h~s  already  been 
done  on  blood  products  by  the  Council  of  Europe,  in particular through  the 
European  Agreement  on  the  Exchange  of  Therapeutic  Substances  of  Human 
Origin9,  to which  the  Community  is a  party,  and  its  recommendations  on  the 
measures  to be  taken  in the  selection and  testing of donors. 
Like  vaccines,  many  blood  products  are  subject  in  the  Member  States  to 
compulsory  testing on  individual  batches  by  a  laboratory  before the  release 
of  the  batch  is authorised.  The  objective of  such  tests is to ensure that 
the  products  are free  of  viral  contaminants  such  as  AIDS  or hepatitis.  The 
Directive therefore authorises  Member  States to retain such  tests, although 
there  should  be  no  unnecessary  repetition  of  them.  The  details  of  the 
tests which  are  required to be  conducted, either by  the  manufacturer  or  the 
state  laboratory,  will  be  specified  in  the  detailed  provisions  for  the 
testing  requirements  of  these  products. 
3.4. Particular  requirements  for  radiopharmaceuticals 
Radiopharmaceuticals  are  medicinal  products  based  upon  radionuclides · 
(radioactive  isotopes)  which  are'  mainly  used  for  diagnostic  purposes. 
Because  many  of  the  radionucl ides  in  common  use  have  relatively  short 
half-lives, ·  radiopharmaceuticals  in  their  ready  to  use  form  are  often 
prepared  in a' hospital  shortly  before their  admi_nistration to  the  patient. 
A  generat.or  is  used  to  produce  a  daughter. ·radionucl  ide  which  is  then 
combined  with  a  carrier  presented  in  the  form  of  a  kit  to ensure  that  the 
radionuclide  is transported to the target organ.  In  Case ;5/85 TISSIER10, 
the  Court  of  Justice  ruled  that  both  the  generator  and  the  kit  must  be 
considered as  medicinal  products,  and  the proposal  therefore envisages that 
marketing  authorization  should  be  required  for  both.  In  addition, 
9  OJ  N°  L 207. of 30.7.1986,  p.  1 
10  Judgement  of  20  March  1986,  not  yet  reported 
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marketing  authorization  is  required  for  radiopharmaceuticals  which  are 
·industrially  p~oduced  in  their  ready-to-use  form.  However, 
authorization  is  not  required  for  a  radiopharmaceutical 
a  marketing 
if  it  is 
reconstituted  in  an  approved  health  care  establishment  by  qualified 
personnel  from  authorized generators,  precursors or  kits  in  accordance  with 
the  manufacturers'  instructions. 
From  the  public  health  point  of  view,  the  principle  factor  which 
differentiates  radiopharmaceuticals  from  other  medicinal  products  is  their 
radioactivity.  The  proposal  makes  special  reference  to  the  relevant 
Euratom  regulations  on  radioprotection.  In  addition,  the  proposal  contains 
detiiled  provisions  on  the  labelling  of  the  different  layers  of  packaging 
of  radiopharmaceuticals  in  accordance  with  international  standards.  In 
~ccordance with  international  practice,  the  informatiorr to  be  labelled on 
the vial  containing  the  radioactive  isotope  is given  in  code,  rather  than 
verbal  form.  Detailed  rules  are also  Laid  down  concerning the  information 
which  must  be  given  to  health  personnel  about  the safe  use  and  disposal  of 
the  product. 
3.5.  Transitional  and  final  provisions 
In  accordance  with  the  prov1s1ons  of  Articles  SA  and  8C  of  the  European 
Economic  Community  Treaty  as  amended  by  the  Single  European  Act,  th.e 
Commission  requests  Member  States  to take  the necessary measures  to  conform 
to  these  Directives  before  1  January  1991;  after  that  date,  all  new 
products  must  comply  with  these  Directives;  regarding  products  which  are 
already  on  the  market  on  the  date of  entry  into force,  the  proposals  allow 
Member  States  the  additional  period  up  to  31  December  1992  in  order  to 
review  and  ensure  that  these  products  comply  with  the  Directives.  Having 
taken  account  of  the structure  and  distribution  of  affected  companies,  it 
does  not  appear,  given  the  information  available  to  the  Commission,  that 
the  harmonisation  proposed  would  have  an  effect  on  the  economies  of  the 
countries  concerned. 
4.  CONCLUSIONS 
The  present  package  of  proposals  constitutes  a  further  step  toward  the 
realisation  of  an  internal  market  for  the  pharmaceutical  sector  by  1992 
with  a  uniformly  high  Level  of  protection  of  public  health  throughout  the 
Community  in  accordance  with  the  provisions  of  Article  100  A 3  of  the 
European  Economic  Community  Treaty  as  amended  by  the  Single  European  Act. 
The  following  additional  proposals  remain  outstanding: 
1988  amendments  to the  veterinary  medicines  directives 
1989  proposals  for  a  definitive  system  for  the  free  movement  of  medicinal 
products  for  human  use  within  the  Community 
1990  information  for  doctors  and  patients  about  medicinal  products 
1990  conditions  of  delivery of  medicinal  products  to patients 
.I  . . 
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PROPOSAL  FOR  A COUNCIL  DIRECTIVE 
amending  Directives 65/65/EEC,  75/318/EEC  and  75/319/EEC  on  the approximation 
of provisions  laid down  by  law,  regulation or administrative action relating 
to proprietary medicinal  products 
THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES, 
Having  regard  to the  Treaty establishing the  European  Economic  Community,  and 
in particular Article 100  A thereof, 
Having  regard to the proposal  from  the  Commission1, 
In cooperation with  the  European  Parliament2, 
Having  regard to the opinion of the  Economic  and  Social  Committee3, 
Whereas  the essential aim  of  any  rules governing  the production,  distribution 
or  use  of  medicinal  products  must  be  to ensure  a  high  level of  protection of 
public health, 
Whereas  the  Directives  on  the  approximation  of  the  laws  relating  to  propri-
etary  medicinal  products  must  be  adapted  to  scientific  progress  and  take 
account  of the experience obtained since their adoption; 
Whereas  in its conclusions of 15  May  1987  on  improvement  in the  use  of propri-
etary  medicinal  products  by  the  consumer4  the  Council  considered  that  the 
system  for  leaflets  accompanying  proprietary  medicinal  products,  for  human 
consumption,  on  the market  in the  Community  should  be  improved; 
1 
2 
3 
4  OJ  N°  C 178, 7.7.1987, p.  2 - 14  -
Whereas  the  guarantees  of  the  quality  of  medicinal  products  manufactured 
within  the  Community  should  be  maintained  by  requiring  compliance  with  the 
principles  of  good  manufacturing practice  for  medicinal  products  irrespective 
of the  ~inal destination of the products; 
Whereas  the  Commission  should  be  empowered  to define  in detail  the principles 
of  good  manufacturing  practice  for  medicinal  products  in  close  cooperation 
with  the  Committee  for  Adaptation  to  Technical  Progress  of  the  Directives  on 
the  Removal  of  Technical  Barriers  in  the  Proprietary  Medicinal  Products 
Sector; 
Whereas  having  regard  to  the  Resolution  of  the  European  Parliament  of 
13  June  1986  on  the  export  of  pharmaceutical  products  to  the  Third  World, 
measures  should  be  taken  to  improve  the  provision  of  information  for  third 
countries about  the  conditions  of  use  of medicinal  products  within  the Member 
States; 
Whereas  the  scope  of  Directive  65/65/EEC5  as  last  amended  by  Directive 
87/21/EEC6  and  Second  Directive  75/319/EEC7  as  last  amended  by  Directive 
83/570/EEC8  on  the  approximation of  provisions  laid down  by  law,  regulation or 
administrative  action  relating  to  proprietary  medicinal  products  should  be 
extended to cover  other  ready-made  medicinal  products  which  do  not  comply  with 
the definition of  proprietary medicinal  produc~s, 
Whereas  in  the  Community  directives  relating  to  medicinal  products  the  word 
•therapeutic" should  be  understood  as  covering  all the  medicinal  purposes  for 
which  a  medicinal  product  may  be  administered  to  human  beings  or  animals, 
which  may  be  to  prevent  or  treat disease,  to  make  a  medical  diagnosis  or  to 
restore,  correct or modify  physiological functions, 
HAS  ADOPTED  THIS  DIRECTIVE: 
5  OJ  No  22,  9~2.1965, p. 369/65 
6  OJ  No  L 15, 17.1.1987, p.  36 
7  OJ  No  L 147, 9.6.1975, p.  13 
8  OJ  No  L 332;, 28;. 11.1983,  p.  1 Article 1 
Council  Directive  65/65/EEC  of  26  January  1965  on  the  approximation of  provi-
sions  laid  down  by  law,  regulation  or  administrative  action  relating  to 
proprietary medicinal  products  is hereby  amended  as  follows: 
1.  In Article 1, the following  points  4  and  5 are  inserted: 
"4  Ready-made  medicinal  product 
Any  medicinal  product  prepared  in advance  which  does  not  comply  with  the 
definition  of  proprietary  medicinal  products  and  which  is  marketed  in  a 
phar'mat:eutical  form  which  may  be  used  without  further  industrial proces-
sing. 
5  Therapeutic 
. The  medicinal  purpose  for  which  a  medicinal  product  is  administered  to 
human  beings or animals,  as  specified in point  2." 
2.  Article 2  is amended  as  follows: 
"The  provisions  of  Chapters  II to  V shall  apply  to  medicinal  products  for 
human  use  intended  to  be  placed  on  the  market  in  Member  States  in  the 
form  of  proprietary  medicinal  products  or  ready-made  medicinal  products 
to the  exclusion of  medicinal  products  which  are prepared  extemporaneous-
ly  in an  individual  pharmacy  for  individual patients." 
3.  In the title, preamble  and  Chapters  II to V all references  to "proprietary 
medicinal  product"  or  to  "proprietary  product"  shall  be  replaced  by 
•medicinal  product". - 16  -
4.  In Article 4a, the following  point 6.6.  is inserted: 
"6.6.  special  precautions  for  disposal  of  unused  product  or  waste 
materials, if appropriate0 • 
5.  In Article 13, the following point 9  is inserted: 
•9.  special  precautions  for  disposal  of  unused  product  or  waste 
materials, if anyn. 
6.  In  Article 14,  the following  fifth  indent  is added: 
n  - manufacturer's batch number•. 
Article 2 
In  Council  Directive  75/318/EEC  of  20  May  1975  on  the  approximation  of  the 
laws  of  Member  States  relating  to  analytical,  pharmaco-toxicological  and 
clinical  standards  and  protocols  in  respect  of  the  testing  of  proprietary 
medicinal  products,  all  references  to  "proprietary  medicinal  product0  or  to 
"proprietary product" shall be  replaced  by  "medicinal product". 
Article 3 
Council  Directive 75/319/EEC  of  20  May  1975  on  the approximation of  provisions 
laid down  by  law,  regulation or administrative action relating to proprietary 
medicinal  products  is hereby  amended  as  follows: - ·j=  ·17  -
1.  In Article 4, the  text of  paragraph  b  is amended  as  follows: 
•(b)  may  submit  the  medicinal  product,  its  active  principles  or  other 
constituent  materials  for  testing  by  a  State.  laboratory  or  by  a 
laboratory  designated  for  that  purpose  in ,order  to  ensure  that  the 
control  methods  employed  by  the  manufacturer  and  described  in  the 
particulars  accompanying  the  application  in  accordance  with  point  7 
of  Article 4,  second  paragraph,  of  Directive  65/65/EEC  are  satis-
factory". 
2.  In Article 6, the  last  paragraph  is  replaced  by  the following: 
•rhe inclusion  of  a  package  leaflet  in the  packaging of  'over the  counter 
medicinal  products'  shall  be  obligatory  unless  all  the  information 
required by  this Article  can  be  conveyed  on  the packaging  itself  • 
. for the  purposes of  this Article,  'over the  counter medicinal  products' 
are  those  medicinal  products  which  are  placed  on  the  market  with  a  view· 
to  their  direct  sale  to  the  public,  without  the  need  for  a  medical 
prescription,  for  use  in  the  relief  of  minor  illnesses  not  requiring a 
medical  diagnosis. 
In the case of other medicinal  products,  Member  States may  require  tha~ a 
leaflet  be  included with  the  packaging. 
Within  two  years  of  the  date  of  the  adoption  of  this  Directive,  the 
Commission  shall  present  to  the  Council  a  report  on  the  possibility  of 
making  more  systematic  the  use,  and  .more  legible  and  intelligible  the 
content,  of  package  leaflets,  accompanied  if  appropriate  by  suitable 
proposals." - 18  -
3.  In Article 16, the first paragraph  is amended  as  follows: 
"1.  Member  States  shall  take  all  appropriate  measures  to  ensure  that  the 
manufacture  of  medicinal  products  is  subject  to  the  holding  of  an 
authorization.  This  manufacturing  authorization  shall  be  required 
notwithstanding that  the medicinal  products manufactured are  intended 
for export." 
4.  The  following  Article 16a  is inserted: 
•Article 16a 
1.  At  the  request  of  the  manufacturer  or  the  authorities  of  a  recipient 
country,  Member  States shall certify that a  manufacturer of medicinal 
products  is  in  possession  of  the  authorization  referred  to  in 
paragraph  1  of  Article 16.  When  issuing  such  certificates,  Member 
States shall have  regard to the prevailing administrative arrangements 
of the World  Health  Organization. 
2.  The  summary  of  the  product  characteristics  approved  by  the  Member 
State  in  accordance  with  Article 4b  of  Directive  65/65/EEC  shall  be 
annexed  to the certificate. 
3.  When  the  manufacturer  is  not  in  possession  of  a  marketing 
authorisation  in  the  country  of  origin,  he  must  provide  the 
authorities  responsible  for  establishing  the  certificate  referred  to 
in  paragraph  1  with  a  declaration  explaining  why  no  marketing 
authorisation has  ben  obtained." 
5.  In Article 17, the following paragraph  d  is inserted: 
"(d)  demonstrate  that  he  complies  with  the  principles  of  Good  Manu-
facturing  Practices  for  medicinal  products  laid  down  by  Community 
Law." 
••  I "·  ', 
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6.  The  following  Article 17a is inserted: 
•Article 17a 
The  principles  of  good  manufacturing  practi_ces  for  medicinal  products 
r~ferred to in Article 17, paragraph  d  shall  be  adopted,  in the  form  of  ~ 
directive  addressed  to  Member  States,  in  accordance  with  the  procedure 
laid down  in Article 2c  of Directive 75/318/EEC."  .. , 
7~  In  the  second  paragraph  of  Article 26,.  the  foll~wing'  subparag~aph_ d  is 
inserted: 
"Cd)  report  periodically  to  the· competent  authprities ··on.  whether  the 
i 
manufacturer  complies  with  the  principles  of.  9~0d  manufacturing 
practices for medicinal  pr·oducts  laid down  by  Community  law". 
8~  Iri  Article 30, the  follo~ing  second.par~graph is inserted: 
•upon  request,  Member  States  shall  forthwi.th  communicate  the  reports 
referred  to  in  subparagraph d  of  the .  second· paragraph  of  Article 26  to 
the  competent  authorities of another Membe~ State.  If, after  consideri~g 
the  reports,  the  Member  State  receiving  the  reports ·considers  that  it 
cannot  accept  the  conclusions  re~ched  by-~he  competent  authority  of  the 
Member  State  in.  which  the  report  was  established,  it  sha.ll. inform  the 
competent  authority  concerned  of  its· reasons  and  may  request  that . a 
further  inspection of the manufacturing establishment  be -~arried out.  I;f 
the  Member  States  concerned  are  unat;>Le  .~o· reach_·  agr_eement, 
forthwith  inform  th~ Commission." 
they  sha.ll. 
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9.  The  following  paragraphs  2  and  3  are  added  to Article 33: 
· "2.  The  person  responsible for  the marketing of a  medicinal  product  shall · 
be  obliged  to notify  the  Member  States forthwith  of any  action taken 
by  him  to suspend the marketing of  a.  product or to withdraw  a  product 
from  the market,  together with  the  reasons for  such  action.  Member 
States shall ensure that  this  information is brought  to the attention 
of  the  Committee  forthwith. 
3.  Member  States shall ensure that  appropriate  information about  actions 
taken  pursuant· to  paragraphs 1 .and  2  which  may  effect  the protection 
of  public  health  in· third  countries· is  forthwith  brought  to  the 
attention  of ·the  World  Health  Organization  with  ·a  copy  to  the 
Committee." 
10.  The  first paragraph·of.Article 34  is hereby  amended  as follows: 
"  •rhis  directive  shall  apply  to  medicinal  products  for  human  use  in  the 
form  of· pr.opr·ietary ·medicinal  pr.oducts  or  ready-made ·medicinal  products. 
to the exclusion of .medicinal  products which·are·prepared extemporaneous-
ly  in an  individual pharmacy  for  individual  patients." 
11.  With  the exception of the first paragraph  of Article 34, all  references  to 
"proprietary  medicinal  product"  or  to  "proprietary  product"  shall  be 
replaced  by  medicinal  product. 
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Article 4 
1.  Member  States  shall  take  the  measures  necessary  to  comply  with  this 
directive  not  later than  1  January  1991. 
Commission  thereof. 
T~ey shall  fo~thwith inform  the 
2.  Requests  for  marketing  authorization  lodged  after-the.ti~e-limit referred 
to  in  the first  paragraph  must  comply  with , the  provtsions  of  this  Di rec-: 
tive. 
3.  A.rt i cles 1, 
progressively 
2  and  3  of·  tbis 
extended  to. 
31  December  1992. 
Article  5 
where  -relevant,  .  ·:  . 
.  .,  . 
Di.recti·ve, 
existing  medicinal  .  .  products 
. ' .  .  -
'. 
shall.  be. 
befor:e 
T~is Directive  is addressed  to the  Memb~r States. 
:  .'; 
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PROPOSAL  FOR  A COUNCIL  DIRECTIVE 
extending  the  scope of  Directives 65/65/EEC  and  75/319/EEC 
on  the  approximation of  provisions  Laid  down  by  law,  regulation 
or  administrative action  relating to proprietary medicinal  products 
and  Laying  down  additional  provisions  for  immunologic~l medicinal 
products  consisting of  vaccines, .toxins or  serums  and  allergens 
- THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES, 
Having  regard to the  Treaty establishing the  European  Economic  Community,  and 
in particular Article  100  A thereof, 
.  d  h  lf  h  c  .. 1  Hav1ng  regar  to t  e  proposa  rom  t  e  omm1ss1on  , 
In ·cooper•tion  with  the  European  Parliament2, 
Having  regard  to the opinion of  the  Economic  and  Social  Committee3, 
Whereas  disparities  in the  provisions  laid  down  by  Law,  regulation or  adminis-
trative  action  by  Member  States  may  hinder  trade  in  immunological  products 
within  the  Community, 
Whereas  the essential  aim  of  any  rules  governing  the  production,  distribution 
or  use  of  medicinal  products  must  be  to  ensure  a  high  level  of  protection of 
public  health, 
1 
2 
3 
I. 
l·: 
I ... 
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Whereas  the  provisions  Laid  down  by  Directive  65/65/EEC4  as  Last  amended  by 
Directive  87/21 /EEC 5  and  Second  Directive  75/319/EEC6  as  Last  amended  by 
Directive  83/570/EEC7  on  the  approximation  of  provisions  Laid  down  by  Law, 
regulation  or  administrative  action  relating  to  proprietary  medicinal  pro-
ducts,  although  appropriate,  are  inadequate  for  immunological  medicinal 
products  consisting  of  vaccines,  toxins  or  serums  and  allergens, 
Whereas  in  accordance  with  Article  5  of  Directive  87/22/EEC8  on  the  approxima-
tion  of  national  provisions  relating  to  the  placing  on  the  market  of  high 
technology  medicinal  products,  particularly those  derived  from  biotechnology, 
the  Commission  is  required  to  submit  proposals  to  harmonise,  along  the  lines 
of  Directive  75/319/EEC  the  conditions  for  authorizing  the  manufacture  and 
placing  on  the  ~arket  of  immunological  medicinal  products  before  22  December 
1987; 
Whereas,  before  an  authorization  to  market  an  immunological  product  can  be 
granted,  the  manufacturer  must  demonstrate  his  ability  to  attain  batch-to-
batch  consistency; 
------------------------
4  OJ  No  22,  9.2.1965,  p.  369/65 
5  OJ  No  L  15,  17.1 .1987,  p.  36 
6  OJ  No  L  147,  9.6.1975,  p.  13 
7  OJ  No  L  332,  28.11.1983,  p.  1 
8  OJ  No  L  15,  17.1.1987,  p.  38 - 24  -
Whereas  the  Commission  should  be  empowered  to  adopt  any  necessary  changes  in 
the  requirements  for  the  testing of  proprietary medicinal  products  set  out  in 
the  Annex  to Directive  75/318/EEC9  of  20  May  1975  on  the  approximation  of  the 
laws  of  the  Member  States  relating  to analytical,  pharmaco-toxicological  and 
clinical  standards  and  protocols  in  respect  of  the  testing  of  proprietary 
medicinal  products,  as  last  amended  by  Directiye  87/19/EEt10  of  22  December 
1986 to take account  of the special nature of  immunological  medicinal  products 
in  close  cooperation  with  the  Committee  for  the  Adaptation  to  Technical 
Progress  of  the  Directives  on  the  Removal  of  Technical  Barriers  to  Trade  in 
the Proprietary Medicinal  Products  Sector; 
HAS  ADOPTED  THIS  DIRECTIVE: 
------~-----------------
9  JO  No  l  147, 9.6.1975,  p.  1 
10 OJ  No  l  15, 17.1.1987, p.  31 ·  . ··  .  ":"  z; ·25  -
Article 1 
1.  In derogation from  Article 34  of  Directive 75/319/EEC,  and  subject  to the 
provisions  of  this  Directive,  Directives  65/65/EEC  and  75/319/EEC  shall 
apply to  immunological  medicinal  products  consisting  of  vaccines,  toxins 
and  serums  and  allergen products for  human  use. 
2.  For  the  purposes of this Directive, the  following  definitions shall apply: 
- •immunological  medicinal  product
11  shall  mean  a  product  of  biological 
origin which  is intended  to effect  the  immune  system  and  which  is used  in 
the diagnosis,  prevention or  treatment  of disease.  Included are vaccines, 
toxins  and  serums  and  allergens, 
- "allergen product"  shall  mean  any  product  which  is  intended to  identify 
or  induce  a  specific  acquired  alteration in  the  immunological  response  to 
an  allergising agent, 
- vaccins,  toxins and  sera shall have  the meaning  assigned to them  in the 
Annex  of  Directive 75/319/EEC. 
Article 2 
1.  The  quantitative  particulars  of  an  immunological  medicinal  product  shall 
be  expressed  by  mass  or  by  international  units  or  by  units  of  biological 
activity or by  protein content  as  appropriate to the product  concerned. 
2.  In  Directives  65/65/EEC  and  75/319/EEC  the  expressions 
11qua l itative  and 
quantitative  particulars  of  the  constituents"  shall  also  include 
particulars  relating  to  biological  activity  or  to  protein  content  and 
"qualitative  and  quantitative  composition
11  shall  include  the  composition 
. of  the  product  expressed  in  terms  of  biological  activity  or  of  protein 
content. 
3.  Whenever  the  name  of  an  immunological  medicinal  product  is expressed,  the 
common  or  scientific  name  of  the  active  constituents  shall  also  be 
included. - 26  -
Article 3 
In  addition  to  the  information  referred  to  in  Article 4a  of  Directive 
65/65/EEC,  the  summary  of  product  characteristics  referred  to  in  point  9  of 
the  second  paragraph  of  Article 4  of  Directive  65/65/EEC  shall  contain  the 
following  information  in  respect of  immunological  products: 
- under  point  5.4,  information  about  any  special  precautions  to  be  taken  by 
persons  handling  the  immunological  medicinal  product  and  persons  adminis-
tering  it  to  patients,  together  with  any  precautions  to  be  taken  by  the 
patient. I 
j• 
,. 
I 
i 
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Article  4 
1.  Member  States  shall  ensure  that  the  manufacturing  processes  used  in  the 
manufacture  of  immunological  products  are  properly  validated  and  attain 
batch-to-batch  consistency.  To  this  end  the  competent  authority  may 
submit  samples  from  up  to  five  in  total  of  the  bulk  and/or  finished 
product  batches  for  testing  by  a  state  laboratory  or  a  laboratory 
designated  for  that  purpose,  either  during  the  examination  of  the 
application  pursuant  to  Article 4  of  Directive  75/319/EEC,  •or  after  a 
marketing  authorisation  has  been  granted. 
2.  For  the  purpose  of  implementing  Article 8  of  Directive  65/65/EEC  and 
Article  27  of  Directive  75/319/EEC,  Member  States  may  require  persons 
responsible  for  marketing  immunological  products  to  submit  to  a  competent 
authority  copies  of all the  control  reports  signed  by  the  qualified  person 
in  accordance  with  Article  22  of  Directive  75/319/EEC. 
3.  Where  it  considers  it  necessary  in  the  interests  of  public  health,  a 
Member  State  may  require  persons  responsible  for  marketing  the  live 
vaccines,  vaccines  used  in  the  primary  immunization  of  infants,  or 
vaccines  used  in  public  health  immunization  programmes,  which  are  listed 
in  the  Annex  to  this  Directive  to  submit  to a  competent  authority  samples 
from  each  batch  of  the  bulk  and/or  finished  product  for  examination  by  _a 
state  laboratory  or  a  laboratory  designated  for  that  purpose  before 
release  onto  the  market,  unless  the  competent  authority of  another  Member 
State  has  previously  examined  the  batch  in question  and  declared  it to  be 
in  conformity  with  the  approved  specification.  Member  States  shall  ensure 
that  any  such  examination  is  completed  within  60  days  of  the  receipt  of 
the  samples.  The  Annex  to this  Directive  containing  the  list of  vaccines 
which  may  be  submitted  for  examination  prior to  release  may  be  amended  in 
accordance  with  the  procedure  laid  down  in  Article  2c  of  Directive 
75/318/EEC •. - 28  -
Article  5 
Any  amendments  which  are  necessary  in  the  testing  requirements  for  medicinal 
products  set  out  in  the  Annex  to  Directive  75/318/EEC  to  take  account  of  the 
extension  of  the  scope  of  Directives  65/65/EEC  and  75/319/EEC  to  cover  immuno-
logical  medicinal  products  shall  be  adopted  in  accordance  with  the  procedure 
laid  down  in  Article  2c  of  Directive  75/318/EEC.  Any  such  amendments  shall 
come  into effect  on  the  same  date  as  this  Directive. 
Article  6 
1.  Member  States  shall  take  the  necessary  measures  to  comply  with  this 
Directive  not  later  than  1  January  1991.  They  shall forthwith  inform  the 
Commission  thereof. 
2.  Requests  for  marketing  authorization.for  products  covered  by  this  Direc-
tive  lodged  after  the  time-limit  referred  to  in  the  first  paragraph  must 
comply  with  the  provisions of this  Directive. 
3. ·  This  Directive  shall  be  progressively  extended  to  the  existing 
immunological  medicinal  products  before  31  December  1992. 
Article  7 
This  Directive  is  addressed  to  the  Member  States. .·. 
! 
i 
.; 
ANNEX 
LIST  OF  VACCINES  REFERRED  TO  IN  ARTICLE  4(3) 
Vaccines  for  human  use,  presented or used  for  the prophylaxis  of  the  following 
diseases: 
Cholera  .' 
Diphtheria 
Hepatitis 
Influenza · 
Measles 
Mumps 
Pertussis 
Polio 
Rabies 
Rubella 
Tetanus 
Tuberculosis 
Typhoid 
Yellow  Fever 
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PROPOSAL  FOR  A COUNCIL  DIRECTIVE 
extending  the  scope  of  Directives  65/65/EEC  and  75/319/EEC 
on  the  approximation of  provisions  laid down  by  law,  regulation 
or administrative action  relating to  proprietary medicinal  products 
and  laying down  additional  provisions  for 
medicinal  products derived from  human  blood 
THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES, 
Having  regard to the-Treaty establishing the  European  Economic  Community,  and 
in particular Article  100  A thereof, 
..  d  h  lf  h  c  .. 1  Hav1ng  regar  to  t  e  proposa  rom  t  e  omm1ss1on  , 
In  cooperation  with  the  European  Parliament2, 
Having  regard  to the opinion· of  the  Economic  and  Social  Committee3, 
Whereas  disparities  in the  provisions  laid  down  by  law,  regulation or adminis-
trative action  by  Member  States may  hinder  trade  in medicinal  products derived 
from  human  blood  within the  Community; 
Whereas  the  essential  aim  of  any  rules  governing  the  production~  distributicin 
or use  of  medicinal  products  must  be  to ensure  a  high  level  of  protection  ~f 
public  health; 
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Whereas  the  .. provisions  Laid  down  by  Directive  65/65/EEC4  as  Last  amended  by 
Directive  87/21/EEC5  and  Second  Directive  75/319/EEc6  ~s  Last  amended  by 
Directive  83/570/EEC7  on  the  approximation  of  provisions  Laid  down  by· Law, 
regulation  or  administrative  action  relating  to  proprietary  ·medicinal  pro-
ducts,  although  appropriate,  are  inadequate  for  med'icirial  products  derived 
from  human  blood; 
Whereas  in  accordance  with  Article  5  of  Directive  87/22/EEC8  on  the  approx~m~­
tion  of  national  provisions  relating  to  the  placing  ~on  the  ma·rket  of'high 
technology  medicinal  products,  particularly those  deri~ed from .biotethnology, 
the  Commission  is  required  to  submit  proposals  to  harmonise~  along  the  Lines 
of  Di.rective  75/319/EEC  the  conditions  for  authorizing  'the  manufacture  and 
·placing  on  the  market  of  medicinal  products  derived  from  hu~a·;i;;blood  before 
22  December  1987; 
Whereas  the  European  Com~unity entirely supports  the efforts·of the  Council  of 
Europe  to  promote  voluntary  and  non-remunerated  blood  donation  to  attain. 
self-suffictency throughout  the  Community  in  the  supply  of  blood  products,  and 
to  ensure  the  respect  of  ethic'al'p~iric·iples'in trade of  therapeut.ic  substances 
of  human  origin; 
Whereas  the  rules  designed  to  guarantee  the  qual  it>:,  safety 
medicinal  products  derived  from  human  blood  mUst  be  appl ie'd  in 
to  both  public  and  private estabU  shment's; 
.  - ..  ------------------------
4  OJ  No  22,  9.2.1965,  p.  369/65 .·· 
5  OJ  No  (  15,  17~~~1987, p •. 36 
6  OJ.No  L  147,  9~6~1975; p.  13 
7  OJ  No:'L332,  28:;)1.1983,  p.  1 
8  OJ  ·No  L  15,  17.;1.1987,  p.  38 
'  ...  ·· .. 
,._. 
and  efficacy of 
.the  same  manner 
.  ·' 
··' 
_,- '. 
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Whereas,  before  an  authorization  to  market  a  medicinal  product  derived  from 
.. human  blood  can  be  granted,  the  manufacturer  must  demonstrate  his  ability to 
guarantee batch-to-batch consistency and  the absence of viral  contamination; 
.Whereas  the  Commission  should  be  empowered  to  adopt  any  necessary  changes  in 
the  requirements  for  the  testing of  proprietary medicinal  products set  out  in 
the  Annex  to Directive  75/318/EEc9  of  20  May  1975  on  the  approximation of  the 
laws  of  the Member  States  relating  to analytical,  pharmaco-toxicological  and 
clinical  standards  and  protocols  in  respect  of  the  testing  of  proprietary 
medicinal  products,  as  last  amended. by  Directive  87/19/EEC  10  of  22  December 
1986 to  take account  of the  special nature  of  medicinal  products derived  from 
human  blood  in  close  cooperation  with  the  Committee  for  the  Adaptation  to 
. Technical  Progress  of  the  Directives  on  .the  Removal  of  Technical  Barriers  to 
Trade  in the:Proprietary Medicinal  Products  Sector, 
HAS  ADOPTED  THIS  DIRECTIVE: 
9  JO  No  L 147,  9.6.1975,  p.  1 
10  OJ  No  L 15, 17.1.1987, p.  31 
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Article 1 
1.  In derogation  from  Article 34  of  Directive  75/319/EEC,  and  subject  to the 
provisions  of  this  Directive,  Directives  65/65/EEC  and  75/319/EEC  shall 
apply  to medicinal  products  based  on  blood  constituents which  are  prepared 
industrially by  public or private establishments,  hereinafter referred to 
as "medicinal  products derived  from  human  blood";  these medicinal  products 
include,  in particular,  albumin,  coagulating factors  and  immunoglobulins 
of  human  origin. 
2.  This  directive shall not  apply  to whole  blood,  to plasma  or to blood  cells 
of human  origin. 
3.  Nothing  in  the  present  directive  shall  in  any  way  derogate  from  Council 
Decision  86/346/EEc11  accepting,  in  the  name  of  the  Community,  the 
European  Agreement  relating  to  the  exchange  of  therapeutic  substances  of 
human  origin. 
Article 2 
1.  The  quantitative  particulars  of  a  medicinal  product  derived  from  human 
blood  shall  be  expressed  by  mass  or by  international units  or by  units of 
biological activity as  appropriate to the product  concerned. 
2.  In  Directives  65/65/EEC  and  75/319/EEC  the  expressions  "qualitative  and 
quantitative  particulars  of  the  constituents"  shall  include  particulars 
relating to biological activity and  "qualitative and  quantitative  composi-
tion" shall  include  the  composition  of  the  product  expressed  in  terms  of 
biological activity. 
3.  Whenever  the  name  of  a  medicinal  product  derived  from  human  blood  is 
expressed,  the  common  or  the  scientific  name  of  the  active  constituent~ 
shall also be  included. 
------------------------
11  OJ  No  L 207,  30.7.1986,  p.  1 - 34  -
Article 3 
In  order  to prevent  the transmission of  infectious diseases,  the  Member  States 
shall take  into consideration the measures  recommended  within the framework  of 
the  Council  of  Europe  and  the World  Health  Organisation  in particular  for  the 
selection and  testing of blood donors. I 
I-
I 
1-
~ 
I-
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Arti<;le  4 
1. ·  Member  States  shall  ensure  that  the  manufacturing·  proc-esses  used•  in' the 
manufactur·e  of  medicinal  products  der-ived  from  hu.i)ah·  blooa  are  properly 
validated,  attain batch-to-batch  consistency  and  guarantee  the  absence  of 
'  I  •  .  ' 
viral  contaminants.  To  this  end  the  competent  au~hori  ty  may  submit 
samples  from  up  to  five  in  total  of  the  bulk  aricJ%~ •finished  product 
,·  /' 
batches  for  testing  by· a  state  labor·atory  or  a  ·tab'c{rat6ry  designated  for 
that  purpose,  eit~e~  d~~ing the:examination of  the·~~~l~~~tion pursuant·.to· 
Article  4  of  Directive  75/319'/EEC,  or after  a  marke't1ng  authorisation  has 
been  granted.  .  .···  ', 
,, -:..·  ,J  ;  I,'''  I./· 
z.  For  the·purpose  of  implementing_Article8  of  D:i:r~ctive  65/65/EEC  and\ 
Article  27  of  Directive  ?S/319/EEC,  Member  States  may  require  persons· 
.  -
·.  ':\~~~~· 
responsible  for  marketing  medicinal  products  derived''f·rom' human' blood  to  . 
submit  to  a competent ·authority  copies  of  alL  the ''cont-rol; ~eports  si  g~ed 
.  . 
by  the· ·qualified  person  in  accordance  ,·with··Article'22-'  .of  Dire~t:iv_e· 
75/319/EEC·.- ·.!  ,;•::-·  ,.)'-,·: •. ·.·:-
3.  Where  it  considers  it  necessary  in  the.  interests  of  public  health,  a 
Member  State  may  require  persons·  reSponsibl~  fo~~·marketirig·-~edicinal 
:products  derived  from  ·human  blood  to  submit  to ·a' competent  . authority 
samplei  from  each  batch  of  the  bulk  and/or  finished  product  for 
examination  by  a  state  laboratory  or  a  Laboratory  designated. for  that 
purpose  before  relee~se onto  the. market,  unless  the  competert  authority· of 
another- Member  State  has  previously  examined  the  batch  in_  question. and · 
declared. it to  be  in  conformity  with  the  approved speci.fications.  ·Member.· 
States shall  ensure that  any·. such  examination  is  c~mpl,eted :within  ~0 day~ 
of  the  receipt  qf 'the  samples.  ·c,' 
c  .  ..  . 
. . f'  .;  : ..  •,  .  ...  ~ . 
·.'  :! 
~  '  •  ••  :  • ·:  •  l""'  - : .:  • 
.  :·  '  ·~. •.  •  •  •  H  .:  ,(..:,  •  ; 
.  . .  ..  ·~.  .... ).,  ,.  ;.: .  .~.  : ' 
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Article  5 
Any  a~endments  which  are  necessary  in  the  testing  requirements  for  medicinal 
products  set  out  in  the  Annex  to  Directive  75/318/EEC  to  take  account  of  the 
extension of  the  scope  of  Directives 65/65/EEC  and  75/319/EEC  to cover  medici-
nal  products  derived· from  human  blood shall  be  adopted  in accordance  with  the· 
procedure  laid down  in Article  2(c)  of  Directive  75/318/EEC.  Any  such  amend-
ments  shall  come  into effect  on  the  same  date  as  this  Directive. 
Article 6 
1.  Member  States  ..  shall  take  the  necessary  measures  to . comply  with  this· 
Directive not  later than  1  January  1991.  They  shall  forthwith  inform  th~ 
Commission  thereof • 
.  2.  Requests  for  marketing  authorization  for  products  covered  by  this  Direc-
tive  Lodged  after  the  time-limit  referred  to  in  the  first  paragraph  must 
comply  with  the  provisions of  this  Directive. 
3.  Thi.s  Direct:ive  s.hall  be  progressively  extended  to  the  existing  medicinal 
products ,derived  from  human  blood,  referred  to  in  Article  1,  paragraph  1 
before.31  December  1992. 
Article 7 
This  Directive  is  addressed  to the  Member  States. 
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PROPOSAL  FOR  A COUNCIL  DIRECTIVE 
extending  the  scope of  Directives 65/65/EEC  and  75/319/EEC 
on  the  approximation of  provisions  Laid  down  by  Law,  regulation 
or  administrative  action  relating to proprietary medicinal  products 
and  Laying  down  additional  provisions  for  radiopharmaceuticals 
THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES, 
Having  regard  to the  Treaty establishing the  European  Economic  Community,  and 
in  pa~tic~lar Article 100  A thereof, 
Having  regard  to the  proposal  from  the  Commission1, 
In  cooperation  with  the  European  Parliament2, 
Having  regard  to the opinion of  the  Economic  and  Social  Committee3, 
Whereas  disparities  in  the  provisions  currently  laid  do~n by  Law,  regulation 
or  administrative  action  by  Member  State~  may  hinder  trade  in  radiopharmaceu-
ticals within  the  Community; 
Whereas  the  essential aim  of  any  rules  governing  the  production,  distribution 
or  use  of  medicinal  products  must  be  to  ensure  a  high  level  of  protection  of 
public  health; 
t 
2 
3 
_.l - 38  -
Whereas  the  prov1s1ons  laid  down  by  Directive  65/65/EEC4  as  last  amended  by 
Directive  87/21/EEc5  and  Second  Directive  75/319/EEC6  as  last  amended  by 
Directive  83/570/EEC7  on  the  approximation  of  provisions  laid  down  by  law, 
regulation  or  administrative  action  relating  to  proprietary  medicinal  pro-
ducts,  although  appropriate are  inadequate  for  radiopharmaceuticals; 
Whereas  in  accordance  with  Article  5  of  Directive  87/22/EEC8  on  the approxi-
mation  of  national  provisions  relating  to  the  placing  on  the  market  of  high 
technology  medicinal  products,  particularly those derived  from  biotechnology, 
the  Commission  is  required  to  submit  proposals  to  harmonise,  along  the  Lines 
of  Directive  75/319/EEC,  the  conditions  for  authorizing  the  manufacture  and 
placing  on  the  market  of  radiopharmaceuticals  before  22  tiecember  1987; 
Whereas  in  the  case  of  radiopharmaceuticals  authorization  should  be  required 
for  industrially prepared  radiopharmaceuticals,  generators,  kits  and  precursor 
~adiopharmaceuticals; whereas,  however,  a  separate authorization should not  be 
required  for  radiopharmaceuticals .;n  their  finished  form  which  are  made  up 
exclusively  from  authorized  kits,  generators  or  precursor  radiopharmaceuticals 
in health  care establishments; 
4  OJ  No  22,  9.2.1965,  p.  369/65 
5  OJ  No  L 15, 17.1.1987, p.  36 
6  OJ  No  L 147, 9.6.1975,  p.  13 
7  OJ  No  L 332,  28.11.1983,  p.  1 
8  OJ  No  L 15, 17.1.1987, p.  38 
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Whereas  the  Commission  should  be  empowered  to  adopt  any  necessary  changes  in 
the  requirements  for  the  testing of  proprietary medicinal  products  set  out  in 
the  Annex  to  Directive  75/318/EEC9  of  20  May  1975  on  the  approximation  of  the 
Laws  of  the  Member  States  relating  to  analytical,  pharmaco-toxicological  and 
clinical  standards  and  protocols  in  respect  of  the  testing  of  proprietary 
medicinal  products,  as  last  amended  by  Directive  87/19/EEc10  of  22  December 
1986  to  take  account  of  the  special  nature  of  radiopharmaceuticals  in  close 
cooperation  with  the  Committee  for  the  Adaptation  to  Technical  Progress  of  the 
Directives  on  the  Removal  of  Technical  Barriers  to  Trade  in  the  Proprietary 
Medicinal  Products  Sector; 
Whereas  any  rules  governing  radiopharmaceuticals  must  take  into  account  the 
provisions  of  Directive 84/466/Euratom11  of  3  September  1984  Laying  down  basic 
measures  for  the  radiation  protection  of  persons  undergoing  medical  examina-
tion  or  treatment;  whereas  account  should  also  be  taken  of  Directive 
80/836/Euratom  12  which  amends  the  Directives  laying  down  the  basic  safety 
standards  for  the  health  protection of  the  general  public  and  wor~ers against 
t.he  dangers  of  ion1z1ng  radiation  as  last  amended  by:  Council  Directive 
-,:  .  .  13 
84/467/~ura~o~  ~f 3  September  1984,  the objective.of which  is to prevent  the 
:·  ~. 
· ~xposure of  wdrkers  or  patients  to  excessive  or  unnecessarily  high  levels  of 
: {oniz:ing  radia:tion,  and  in  particular of  Article  Sc  thereof,  which  requires 
Jr1o.r  .authoris~t,ion  for  the  addition  of  radioactive  substances  to  medicinal 
'  p:roducts  as  well· as  for  the  importation of  such  medi.cinal  products, 
HAS  ADOPTED  THjS  'DIRECTIVE: 
--------------~---------
9  OJ  No  L 147,;9.6.1975,  p.  1 
10  OJ  No  L  1S,l17.1.1987,  p.  31 
11  OJ  No  L 265;  5.10.1984,  p.  1 
12  OJ  No  L 246;  17.9.1980,  p.  1 
13  OJ  No  L 265,  5.10.1984,  p.  4 .. 
} 
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Article 1 
1.  In  derogation  from  Article  34  of  Directive  75/319/EEC  and  subject  to the 
provisions of  this Directive,  the provisions  of  Directives  65/65/EEC  and 
75/319/EEC  shall  apply  to  radiopharmaceuticals  for  human  use,  excluding 
radionuclides  in the form  of  sealed sources. 
2.  for  the  purposes of this directive, the  following  definitions  shall apply: 
- •radiopharmaceutical'  shall mean  any  medicinal  product  which,  when  ready 
for  use,  contains  one  or  more  radionuclides  (radioactive  isotopes) 
included for  a  medicinal  purpose, 
- •generator•  shall  mean  any  system  incorporating  a  fixed  parent 
radionuclide from  which  is produced  a  daughter  radionuclide  which  is to be 
removed  by  elution and  used  in a  radiopharmaceutical, 
- 'kit'  shall  mean  any  industrial  preparation  to  be  reconstituted  or 
combined  with  radionuclides  in  the  final  radiopharmaceutical,  usually 
prior to its administration, 
- 'precursor  radiopharmaceuticaL•  shall  mean  any  other  industrially 
produced  radionuclide  for  the  radio-labelling  of  another  substance  prior 
to administration. 
3.  Nothing  in  this -directive  shall  in  any  way  derogate  from  the  Community 
rules  for  the  radiation  protection of  persons undergoing  medical  examina-
tion or treatment .or  from  the  Community  rules  laying down  the  basic safety 
. standards  for  the  health. protection  of  the  general  public  and  workers 
against  the dangers of  ionizing radiation; 
c  • .••  .',:l.  ~~+  41  -
Article 2 
The  authorization  referred  to  in  Article  3  of  Directive  65/65/EEC  shall  be 
required for generators, kits, precursor  radiopharmaceuticals  and  industrially 
prepared  radiopharmaceuticals.  However,  authorization shall  not  be  required 
for  a  radiopharmaceutical  in its ready  for  use  form,  if the  radiopharmaceuti-
cal  is prepared by  an  approved  person  in an  approved  health  care establishment 
exclusively from  authorized generators,  kits or precursor  radiopharmaceuticals 
in accordance  with  the manufacturer's  instructions. 
Article 3 
In  addition  to  the  requirements  set,out  in  Article 4  of  Directive 65/65/EEC, 
an  application  for  authorization  to market  a  generator  shall also  contain  the 
following  information and  particulars: 
-a general  description of  the  system  together with  a  detailed  description of 
the  components  of  the  system  which  may  effect  the  composition  or  quality  of 
the daughter nucleid  preparation, 
- qualitative and  quantitative particulars of  the eluate. 
Article 4 
For  radiopharmaceuticals,  in  addition  to  the  information  referred  to  in 
Article 4a  of  Directive  65/65/EEC,  the  summary  of  product  characteristics 
referred  to  in  point  9  of  the  second  paragraph  of  Article 4  of  Directive 
65/65/EEC  shall contain the following additional  points  7  and  8: 
"7.  full details of  radiation dosimetry; - 42  -
8.  Additional detailed  instructions for  preparation,  and  where  appropriate, 
maximum  storage time  during which  any  intermediate  preparation such  as  a~ 
eluate  or  the  ready  to  use  pharmaceutical  will  conform  with  its 
specifications." 
Article 5 
The  outer  carton  and  the  tin  of  medicinal  products  containing  radionudides 
shall be  Labelled  in accordance with  the  regulations  for  the safe transport  of 
radioactive  materials  laid  down  by  the  International  Atomic  Energy  Agency. 
Moreover,  the  labelling shall  comply  with  the  following  provisions: 
a)  The  label  on  the  shielding  shall  include  the  particulars  mentioned  in 
Article 13  of  Directive  65/65/EEC.  In  addition,  the  labelling  on  the 
shielding  shalL  explain  in  full  the  codings  used  on  the  vial  and  shall 
indicate,  where  necessary,  for  a  given  time  and  date,  the  amount  of 
radioactivity  per  dose  or  per  vial  and  the  number  of  capsules  or,  for 
liquids, the number  of millilitres in the container; 
b)  The  vial shall.be  Labelled with  the  following  information: 
~  ·  -the name  or  code  of the medicinal  product  includin~ the-name  or  chemical 
. symbol  of the  radionuclide 
the batch  identification and  expiry date 
- the  international symbol  for  radioactivity 
- the name  of the manufacturer 
- the amount  of  radioactivity as specified under  a>  above 
- ., 
~  ) 
. i 
·.  i 
i 
1 
l 
·j 
' ,_:·· 
- 43  -
Article 6 
·.":. 
1. 
2. 
Member  States shall ensure. that  a  detailed'instructi.o~'·leaflet  is.enclosed 
~  ..';,_  ~----·:  ,  .:·:  :, ';;J·r_·.:  ·_,  ::_;~  >J~  :·  .  ,-:  ~-
with  the  packaging of  radiopharmaceu~icals;  generators~kits or  precursor  · 
'  ·  ·  ~--'  .·:  ;-_;;.  r  ~  ~  .  ;  ~··  ~.  ·,·A\L~:~';  .-f~. t  ~-~-~~  ·  ·  ·  ·'  ·  . /'  . 
radiopharmaceuticals.  The  text  of this leaflet ··shall  be.<establ i.shed  .in" 
'  · ••  !  ,  .. :  :  :  '.' •':  ;  .  ·.'· '·'  :'~ ·: ':•.'r·  ('.(  '  '\  ' 
accordance  with  the  provisio~s  of  A~ticle 6·  of  o'irettive'.i.S/319/EEC  and  · 
shall  contain all the  infor~ation."r~f;~red to  tih.ere~n.:  .. ,;. ~~,·~~ddi,tion,. the 
.  •  '  '  -;  •  •  •.  t  .'  I  , .•  ,  '·  ' 
leaflet  shall  include  any. pr.ecautiOf:!S  tO. ~e  tak~n~ by  the .user. and  the 
.  '··~.: ··.  ~  '.J-~ \.' -.·  '\  '  :  ','  ,._.)  ~-~·~{  _·  •. :·/  --~:.'  ..  ·· 
patient  during  the  preparation  ahd 'administra:tion  o.f  the  product  and 
~.;  .  .::,  .•  ::--:,~-~~  ._:.~·- .•. ...  !:,'.  --~2~~~.:;,:~~--- ·.  !·_·;·_._·:~·:  ~  ·-~.:  ::  .:,? 
special  precautions  for  the  disposaL  of  the  conta~ner  and  . its  .unused 
.  .  '  .  .  •  . f;- .~  :  .t', ·.:_  ;  -:·.  >.  _,,-:·_-;:...  :.--__ ;·" ; ..  . 
contents. 
::.: 
.  •.  .  ·. 
Member  States shall  permit  th~. ~s~ ?: ~~s~f.  )nf~·rmat.i:~·"t·t_e,~~l~·f.s  ..  ~~/c~  h~ve: 
been  established  in  more. than . one  of  ~he  ~a:nguages  of  the  Coinmun;ty 
provided  that  the  info.rmati~·~ .·~~ntain~·~  i~·' atl': the  ·l~~~u~~~;  ve'rsi~·~~  ·.~:1  ·~· 
o  '  >  - ~  ,I •  <  '  '  I  I  '  '  r  0  j  j  0  >  • :i  ":  '  ,; •  ~  o;•  ~• 
the  leaflet is  identtc~l~  . .  .  1 .. 
'  ;  -•·" ;.'  . ::  ~ 
~ ··'Article 7 
'.:·  .•  ·.:  ·J .• j  ••  ' 
Ahy  amendment~  which  ·are  necessar:y:  in  th~  .. testi.ng .re~uir~m.e:n:ts. for  medi~~~~L 
products set  out  in  the  Annex  to 'Directive  75/3.1:8/EEC  ~o  t~.ke ·~:~:count  of,;'~~~: 
extension of  t,he  scope  of  Directives· 65/65/EEC  and  75/3;19/EEC  to  cover  radio-· 
ph~rmaceuti  ca ls shall  be  a~opted ·in  a~cordance .w; th! ::t,he  .p.~o·~~~~,:;e  'l~~cf'd~wn,:  i~ 
•  ·. :  ... •  •  '  .  .  .•;•  ' • :  :  ::•  ,·  '.  ~  ;:- :  ..  :.:,  ,  .::  .: •  ~.  ·.  .  ~ ''  :.  - ~.: ~':.: •  •  ·I  '.  :I '  ~  :  '~  {  . 
Article  2  c.  of  pi·recti.ve  75/318,/EEC  •..  Ariy  suc:h  a.me.ndments  shal~>come  in~Q:  . 
.. -·,i.  ; ·-- ...  "  l•.  ".  '•.  •  ,.1 
-~  ~ .· 
.  '-q. 
; .•  t  - ~  :  .  (  ~  .. ·,  .,  . 
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Article 8 
1.  ·  Member  · States  ·shaLl  take  ·the  necessary  measures  to  comply  with  th·is 
Directive  not-later~than 1  January  1991.  They  shall  forthwith  inform the 
Commission  thereof. 
2~ ·  Requests  for  marketing  authorization  for  products  covered  by  this  Direc- · 
. ·tive  Lodged  after· the  time-limit  referred  to  in  the  first  paragraph· must· 
comply  with  the  provisions  of  this  Directive. 
3 •.  This  Directive  shall  be  progressively  extended: to  existing  medicinal 
products  covered  by  this  Directive before  31  December  1992. 
Article 9 
··;  ·This  Dir:ective  is-addressed.to the  Member  States.  · 
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FINANCIAL  STATEMENT 
RELATING  TO  THE  EXTENSION  OF  THE  COMMUNITY  PHARMACEUTICAL  DIRECTIVES 
TO  MEDICINAL  PRODUCTS  NOT  YET  COVERED 
BUDGET  HEADINGS 
N°  A 2511  (travelling expenses  of  members  of  committees) 
N°  B 7750  (biological  standardization/contract  for  provision of  services 
with  the  European  Pharmacopoeia) 
2.  LEGAL  BASIS 
- Article 100  A of  the  EEC  Treaty 
-Mandate  from  the  Council:  Article  5  paragraph  2  of  Directive  87/22/EEC 
(O.J.  L 15  of .17.01.1987) 
3.  DESCRIPTION  OF  THE  PROJECT 
3.1.  General  objective 
To  include  within  Community  law  all  categories  of  industrially  prepared 
medicinal  products  hitherto not  covered,  as  foreseen  by  the  White  Paper 
on  the  Completion  of  the  Internal  Market,  timetable  annex,  p.  17. 
3.2.  Specific objective 
Elaboration  of  specific  standards.  Harmonization  of  the  general 
principles  (Council  framework  directives)  and  the specific  rules  (future 
Commission  directives)  necessary  to  guarantee  the  quality,  safety  and 
efficacy  of  three  additional  categories of  medicinal  products  for  human 
use: 
- immunological  products  (in particular vaccines) 
- radiopharmaceuticals  <radio-isotopes) 
- blood  products  of  human  origin 
3.3.  Second  specific 
preparations 
objectives:  elaboration  of  standard  reference 
Physico-chemical  tests  are  not  sufficient  to  guarantee  the  quality  of 
biological  medicinal  products  (vaccines,  blood  derivates  etc.).  In 
addition,  it  is  important  to  guarantee  the  absence  of  viral 
contamination  (AIDS,  hepatitis  B).  The  elaboration  of  biological 
preparations  which  can  serve  as  reference  standards  at  European,  even 
world-level,  is  therefore  indispensable,  both  for  the national  testing 
Laboratories  and  for  the  manufacturers  of  biological  medicinal  products • 
'  ·~··  ..  '  :~ ;, ..  .  ;...  '  .. - 47  -
4.  JUSTIFICATION  OF  THE  PROJECT 
4.1.  Justification of  the  type  of  project  proposed 
The  very  considerable  technical  specificity  of  these  new  categories  of 
medicinal  products  requires substantial  changes to the  testing standards 
applicable  to  other  medicinal  products  already  covered  by  Community 
legislation. 
The  elaboration  of  international  biological  reference  preparations 
requires  collaborative  studies  between  the  major  national  testing 
laboratories,  then  the  adoption  of  a  common  standard  and  finally  the 
stockage  and  distribution of  this standard  by  a  reference  centre.  The 
European  Pharmacopoeia  (CounciL  of  Europe)  is  the  European  institution 
best  suited  for  this  role. 
4.2.  Interest  of  the  project  at  Community  Level 
The  realisation  of  the  internal  market  implies  that  all  categories  of 
industrially  produced  medicinal  products  must  be  able  to  circulate 
throughout  the  Community.  Three  categories  covered  here  are 
particularly  important  for  public  health,  but  also  present  problems  of 
standardization  which  the  Member  States  will  be  better placed  to  resolve 
together  rathen  than  separately.  Because  of  product  liability  and  the 
risks  attached  to  vaccines  (virulence),  to  blood  products  <AIDS, 
hepatitis)  or  to  radiopharmaceuticals  (radioactivity),  European  firms 
are  tending  to  leave  these sectors,  which  are nevertheless vital  for  the 
prevention  and  treatment  of disease. 
5.  FINANCIAL  IMPLICATIONS 
a)  Additional  personnel  required  for  DG  III/8/6,  from  1989,  would  be  one 
administrator  <A7)  and  one  secretary,  to  be  found  by  internal 
redeployment  or  through  normal  budgetary  process. 
b)  Appropriations  for  three  new  committees  from  1989  (vaccines,  blood, 
radiopharmaceuticals)  with  4  meetings  a  year  for  each  of  them,  thus 
12  in total:  +  60  000  ECU  per  year.  The  provision  of  funding  will  be 
considered  in-the  context  of  the  overall  budget  which  will  be  granted 
by  the  budgetary  authority  under  the  heading  2511. 
c)  Contract  for  provision  of  services  with  the  European  Pharmacopoeia  to 
accelerate  the  standardization  of  international  biological  reference 
p~ep~~ations, to  be  found  frcm  within  budgetary  requests  already  made 
for  1989,  and  for  subsequent  years  from  the  normal  annual  budgetary 
process. 
The  funding  is  estimated as: 
- 300  000  ECU  in  1989 
- 500  000  ECU  in  1990 
800  000  ECU  a  year  in  1991  and  thereafter (l  • 
·. 
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...  __ ,-.-.-_STATEMENT'  OF'' IMPACr ON'" SMAt.l- AND- MEDI OM-SIZED  FIRMS 
AND  EMPLOYMENT 
1.  ADMINISTRATIVE  OBLIGATIONS  ARISING  FROM  THE  APPLICATION  OF  THE 
LEGISLATION  FOR  FIRMS 
Sysiematic  obligation to obtain prior approval  before manufacturing  or 
marketing  immunological  medicinal  products,  medicinal  products  derived  from 
human  blood,  radiopharmaceuticals  and  non-proprietary medicinal  products. 
In  many  cases  such  an  obligation already exists at  national  Level. 
2.  ADVANTAGES  FOR  THE  FIRM 
- YES/N~  - WHICH  access  to a  Community  scale  market  with  greater  Legal 
certainty  as  to the  rules  to  be  applied;  abolition of  repeat 
batch  control  testing 
3.  INCONVENIENCE  FOR  THE  FIRM 
- YES/N~  -obligation to  submit  to  increased  administrative surveillance 
- CONSEQUENCES 
Marginally  increased production  costs  which  should  be  offset  by  access  to 
a  larger  internal market.  The  administrative  controls  envisaged are  not 
disproportionate  with  the  requirement  to  improve  the protection of public 
health  in this sector. 
4.  EFFECT  ON  EMPLOYMENT 
No  direct  effects. 
5.  HAS  PRIOR  CONCERTATION  WITH  THE  SOCIAL  PARTNERS  TAKEN  PLACE? 
- YES/N~  - consultation of pharmaceutical  industry 
OPINION  OF  SOCIAL  PARTNERS- generally  favourable 
6.  IS  THERE  A LESS  RESTRICT~VE ALTERNATIVE? 
No. 
.so 